

Faricimab Biosimilar - Research Grade

Product Code: ICH5320

More Information

Species Reactivity: Human

Target: ANGPT2 + VEGFA

Concentration: 5mg/ml

Isotype: IgG1-kappa-lambda

Host: CHO Cells

product name H2: Faricimab Biosimilar - Research Grade

Sequence: <https://www.imgt.org/mAb-DB/>

Buffer: ICH3002

UniProt: O15123;P15692

Shipping Conditions: Blue ice

background: Dual neutralization of angiopoietin-2 (ANGPT2) and VEGF-A targets two cooperating drivers of pathological angiogenesis studied in retinal and vascular disease. This recombinant bispecific antibody is an unconjugated, non-therapeutic analog of faricimab, supplied for research use only. Manufactured to in vivo standards and purified to low endotoxin, it is offered in scalable milligram (mg) to gram (g) quantities for bulk and high-throughput laboratories. It is suited to dual ligand-neutralization assays, in vitro functional screening, and in vivo angiogenesis and ocular disease models, providing a dependable and reproducible research reagent.

Other names: vascular endothelial growth factor A, VEGF-A, VEGF_angiopoietin 2, Ang2

Purification Method: This monoclonal antibody was purified using Protein A

Formulation: Sterile, preservative-free, solution in PBS. BSA and Azide free.



Purity: >90% by SDS-PAGE

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Storage: This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Applications: Functional Assays

Application Notes: This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.